Skip Navigation



Rheumatology Advance Access published online on September 22, 2009
Rheumatology, doi:10.1093/rheumatology/kep287
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/12/1533    most recent
kep287v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Minnock, P.
Right arrow Articles by Bresnihan, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minnock, P.
Right arrow Articles by Bresnihan, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis

Patricia Minnock1, John Kirwan2 and Barry Bresnihan1,3,4

1Rheumatology Rehabilitation, Our Lady's Hospice, Dublin, 2University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, 3St Vincent's University Hospital and 4University College Dublin, Dublin, UK.

Correspondence to: Patricia Minnock, Rheumatology Rehabilitation, Our Lady's Hospice, Harold's Cross, Dublin 6, Ireland. E-mail: pminnock{at}olh.ie


  Abstract

Objective. Fatigue is an important symptom in patients with RA. Measurement of fatigue in clinical trials and in clinical practice requires scales that are reproducible, sensitive to change and practical. This study examined the reliability and sensitivity to change of fatigue and its relative independence as an outcome measure in RA.

Methods. Successive patients referred to the rheumatology clinic at St Vincent's University Hospital and Our Lady's Hospice were evaluated. Clinical assessments were undertaken at baseline and 3 months after commencing TNF-{alpha} blockade. Fatigue was measured using an 11-point numeric rating scale (NRS). Sensitivity to change when compared with current core set outcome measures was determined by calculation of the standardized response mean (SRM). Multiple regression analysis was employed to determine the independent variance of fatigue scores relative to the core set.

Results. Forty-nine patients were evaluated. At baseline, mean (S.D.) fatigue scores were 6.7 ± 2.1. At 3 months, fatigue scores had fallen to 4.3 ± 2.6 (P < 0.001). Test–retest intraclass correlation coefficient for the NRS was 0.79 (P < 0.008). Fatigue was ranked third for relative sensitivity to change as shown by SRM: pain, 1.37; tender joint count (TJC), 1.09; fatigue, 0.92; swollen joint count (SJC), 0.86; HAQ, 0.82; CRP, 0.69; and patient global health (GH), 0.25. The relative independent variance in fatigue of 22% was higher than that of the core set: TJC, 20%; pain, 19%; SJC, 16%; GH, 8%; HAQ, 7%; and CRP, 8%.

Conclusions. This study demonstrates that measures of fatigue are reliable and sensitive to change, and should be considered for inclusion as a core outcome measure in RA.

KEY WORDS: Rheumatoid arthritis, Pain, Fatigue

Submitted 17 October 2008; revised version accepted 5 August 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.